Home › Compare › SCAXF vs ABBV
SCAXF yields 153846.15% · ABBV yields 3.06%● Live data
📍 SCAXF pulled ahead of the other in Year 1
Combined, SCAXF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SCAXF + ABBV for your $10,000?
Sparta Capital Ltd. provides specialized energy capturing, converting, optimizing, and related services to the commercial sector. It offers viable options for helping manufacturers reduce waste, save resources, save money, and lower their carbon footprint; upcycles end-of-life electronic components; and sequesters C02 emissions through waste diversion and converts biomass waste into consumables. The company also distributes specialized photoluminescent exit signs and egress pathway marking to reduce the consumption of carbon based electricity; and measures and monitors energy use in commercial buildings and manufacturing facilities, as well as offers turnkey solutions and ongoing support. In addition, it delivers energy management and power quality solutions and services, including harmonic mitigation and power factor correction in industrial and commercial areas. Further, the company offers TruckSuite that provides fleet owners/operators with comprehensive maintenance, including roadside emergency assistance; emergency repair with competitive pricing, and complete warranty coverage; TripVision, an integrated vehicle health and safety management system; TreeFrog Transportation Optimization System; and Sparta Health, a streamlined process for accessing personal protective equipment. Sparta Capital Ltd. was incorporated in 1988 and is headquartered in Toronto, Canada.
Full SCAXF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.